The Patent (Amendment) Rules, 2024: What the New Flexibility Gives You — and the Hard Deadlines It Cannot Touch

Introduction

On 15 March 2024, the Patent (Amendment) Rules, 2024 came into force and quietly rewrote the rhythm of patent prosecution in India. Practitioners who had spent two decades telling clients "this deadline cannot be extended, full stop" suddenly found themselves revising standard advice: many timelines that were once immovable can now be bought back, at a price, under the liberalised Rule 138.

But here lies the trap — and it is a trap that has already caught applicants who read the headlines and not the fine print. The 2024 amendments are subordinate legislation made under Section 159 of the Patents Act, 1970. They can soften only those timelines that live in the Rules. Where the Act itself fixes a period and attaches a consequence — "deemed abandoned," "deemed withdrawn," "shall not be entertained" — no Rule, however generously worded, can rescue a defaulting applicant. Only Parliament can.

This article does two things. First, it walks through the salient features of the 2024 amendments with practical illustrations. Second — and this is where most commentary stops short — it maps the boundary line between what the new Rules can extend and what remains a statutory hard wall, so that you never advise a client that Rule 138 will save an application that Section 9(1) has already killed.

---

Part I: The Salient Features of the Patent (Amendment) Rules, 2024

1. Form 1 — Knowing your applicant better

The amended Form 1 now seeks the gender and age of the applicant and inventors, along with the applicant's email and phone number. For natural persons, mentioning age is not mandatory. This is largely a data-hygiene measure aligned with the Patent Office's push toward digital communication — but do update your filing templates, because an incomplete Form 1 invites an avoidable office objection.

2. Form 3 — The foreign filing statement, rationalised

The Statement and Undertaking regarding corresponding foreign applications was, for years, a recurring compliance headache: every development abroad triggered a fresh six-month update obligation. The 2024 Rules bring welcome relief:

The first Form 3 is still due within six months of filing. Thereafter, a fresh Form 3 is required within three months of the issuance of the First Examination Report (FER) if the Controller raises it as an objection — replacing the old rolling six-month updates. The Controller may now himself consult accessible public databases (such as WIPO CASE and Global Dossier) for information on foreign applications, recording reasons in writing, and may call for a fresh Form 3 within two months. Delay of up to three months is condonable on a request made in Form 4.

Example: Suppose Supreme Pharma, an Indian pharma startup, files a patent applcation in India in April 2024 and later files counterparts in the US, EP and JP. Under the old regime, each foreign filing and each office action abroad arguably triggered update obligations. Under the amended Rule 12, Supreme Pharma files its first Form 3 within six months, and then simply refreshes the position once, within three months of the FER — a dramatic reduction in docketing burden and in the risk of an inadvertent Section 8 non-compliance being raised in later revocation proceedings.

3. Divisional applications — Rule 13(2A) settles the debate

The newly inserted Rule 13(2A) expressly permits an applicant to file a further application (divisional) in respect of an invention disclosed in the provisional or complete specification, and even on the basis of a further application already filed — that is, a divisional of a divisional.

This provision legislatively affirms the position taken by the Delhi High Court in Syngenta Ltd. v. Controller of Patents (2023), resolving years of uncertainty over whether a divisional could be anchored in the disclosure of the specification or only in the claims of the parent.

Example: Advanced Battery Concepts, LLC files a complete specification describing both a battery-cooling architecture and a regenerative braking algorithm, but claims only the cooling architecture. Pre-2024, an objection could be raised that a divisional directed to the braking algorithm was impermissible because it was never claimed in the parent. Under Rule 13(2A), Advanced Battery Concepts, LLC may confidently carve out the algorithm into a divisional — and, if that divisional itself discloses two inventions, carve again.

4. Request for Examination — 48 months becomes 31

For applications filed on or after 15 March 2024, the Request for Examination (RFE) under Rule 24B must be filed within 31 months from the earliest priority date, down from 48 months. This aligns the RFE window with the PCT national phase entry deadline and is intended to compress overall pendency.

Practical consequence: applicants can no longer "park" an Indian application for four years while testing the market. The strategic waiting game is over; docket the 31-month date on the day of filing.

5. Grace period — Form 31 gives Section 31 a procedure

Where an invention has been anticipated by the applicant's own public display in circumstances covered by Section 31 (display at a government-notified exhibition, paper before a learned society, etc.), the application may still be filed within twelve months of such display — and the 2024 Rules introduce Form 31 as the formal route to claim this grace period, with prescribed fees and supporting evidence.

Mark this well: the grace period is not automatic. It must be affirmatively invoked on Form 31 with evidence. A generic public disclosure — a product launch, a website posting, an investor pitch deck — typically will not qualify at all, because Section 31 protects only the specified categories of disclosure.

6. Pre-grant opposition — a prima facie filter and tighter clocks

Amended Rule 55(3) introduces a two-stage gatekeeping mechanism. The Controller must first consider whether the representation makes out a prima facie case. If no prima facie case is made out, the opponent is notified; if the opponent requests a hearing, an order recording grounds of refusal must follow within one month of the hearing, and if no hearing is requested, within one month of the notification. If a prima facie case is made out, the Controller passes an order and notifies the applicant within one month of receiving the representation, and the applicant must file its statement and evidence within two months (down from three).

Why it matters: pre-grant opposition had become a favourite delay instrument — serial, often benami, representations could stall grant for years. The prima facie filter lets the Controller summarily dispose of frivolous oppositions, while genuine challenges proceed on an accelerated timetable.

7. Post-grant opposition — the Opposition Board speeds up

Under amended Rule 56(4), the Opposition Board must submit its reasoned report, with a joint recommendation on each ground taken in the notice of opposition, within two months (previously three) from the date the documents are forwarded to it.

8. Certificate of Inventorship — Rule 70A gives inventors their due

A new Rule 70A allows any inventor to obtain a formal Certificate of Inventorship in respect of a granted patent, on a request in Form 8A with the prescribed fee (₹900 e-filing / ₹1,000 physical). Since the Indian patent certificate names only the patentee, this is a meaningful recognition tool — particularly valued by employee-inventors whose employers own the patents, and useful for academic CVs, visas and professional profiles.

9. Renewal fees — a 10% discount for paying ahead

If annual renewal fees are paid in advance for a period of at least four years through the e-filing route, a 10% discount applies. For patentees managing large portfolios, this is a simple, bankable saving — and it also removes the recurring risk of a missed annuity.

10. Form 27 — working statements every three years

The statement of working of a patent (Form 27) is now required once for every three financial years, instead of annually, and a delay of up to three months is condonable on a Form 4 request. Combined with earlier simplifications of the Form itself, the compliance load on patentees has been substantially lightened.

11 & 12. The re-engineered powers of the Controller — Rules 137 and 138

This is the structural heart of the 2024 amendments, and it deserves careful reading.

Rule 137 (general power to amend documents and condone irregularities) is now expressly made subject to a new sub-rule (2), which carves out a list of matters that cannot be handled under Rule 137 — including extensions under Rule 12(5) (Form 3), Rule 20(4)(i) and 20(6), Rule 21, Rule 24B(1), (5) and (6) (RFE and FER response timelines), Rule 24C(10) and (11) (expedited examination), Rule 55(4), Rule 80(1A) (renewal fees), and Rules 130 and 131.

Rule 138 (power to extend time or condone delay), by contrast, has been dramatically liberalised. Notwithstanding anything in the Rules, the Controller may extend the time for doing any act, or condone any delay, for a period of up to six months, on a request in Form 4 made before the expiry of that six-month period — and such requests may be made any number of times within the six-month window. The fee is significant: ₹10,000 per month for natural persons, startups and small entities, and ₹50,000 per month for others.

Read together, the architecture is elegant: the old, discretionary Rule 137 route — available at a modest flat petition fee of ₹1,600 for natural persons, startups, small entities and educational institutions (₹8,000 for others) — is now closed for the critical prosecution deadlines, and in its place stands a transparent but far costlier per-month extension mechanism under Rule 138. You can now buy time — up to six months of it — for almost everything the Rules govern. Which brings us to the question every client eventually asks: almost everything?

---

Part II: The Boundary Line — What Rule 138 Can Never Extend

The governing principle: Rules cannot override the Act

The 2024 amendments — Rule 138 condonation, the softened Form 3 and FER timelines, the Form 31 grace-period procedure — are all subordinate legislation made under the rule-making power in Section 159 of the Patents Act, 1970. Subordinate legislation can regulate only what the parent statute has delegated to it. It follows that Rule 138 can extend only those timelines that are themselves prescribed by the Rules. Where the Act itself fixes a period and states the consequence of default, no Rule — 2024 or otherwise — can override it. A rule that purported to do so would be ultra vires Section 159.

This single principle sorts every deadline in Indian patent practice into two baskets: the extendable (Rules-based) and the immovable (Act-based). The table below lists the principal Act-fixed deadlines that the 2024 amendments do not, and legally cannot, touch.

#	Deadline	Provision	Consequence if missed	Why the 2024 Rules cannot help
1	Filing the complete specification after a provisional — 12 months	Section 9(1)	Application deemed abandoned, automatically	Both the period and the consequence are fixed in the Act itself
2	Convention application — within 12 months of the first application in the convention country	Section 135	Convention priority lost; exposure to opposition/revocation under Sections 25(1)(i)/(2)(i) and 64	Act-fixed period mirroring the Paris Convention priority term
3	Post-grant opposition — notice within 1 year from publication of grant	Section 25(2)	Opposition barred after the year	Period fixed directly in Section 25(2); the 2024 changes touched only the fee and procedure of opposition, not this window
4	Restoration of a lapsed patent — application within 18 months from the date the patent ceased to have effect	Section 60(1)	Restoration barred	The 18-month outer limit is in the Act; the Rules govern only the procedure within that window
5	Request for Examination	Section 11B (period delegated to Rule 24B)	Deemed withdrawn	A special case — see the nuance below, because this one has partly shifted after 2024

Item 1 in depth: Section 9(1) is a statutory guillotine, not a procedural lapse

The 12-month deadline for converting a provisional specification into a complete specification comes from Section 9(1) of the Act — not from the Rules. If the complete specification is not filed within twelve months of the provisional filing date, the application shall be deemed to be abandoned. The abandonment is automatic: no notice, no order of the Controller, no opportunity of hearing. On day 366, the application is legally dead, whether or not anyone at the Patent Office has noticed.

Why the liberalised Rule 138 offers no rescue. Rule 138 lets the Controller extend time for acts and proceedings "under these rules." Filing the complete specification within twelve months is an act required under the Act. Extending it by Rule would be beyond the rule-making power under Section 159. Rule 138 was designed to plug procedural gaps in the Rules — Form 3 filings, FER responses, working statements, RFE — not to resurrect statutory abandonment. This is also consistent with long-standing Patent Office practice even before 2024: no extension has ever been available for this specific deadline, and nothing in the 2024 package changes that.

A cautionary example. Lark Engineering files a provisional specification on 1 June 2024 for a novel Pellet Feed Plant, busy with plant development — misses the 1 June 2025 deadline for the complete specification. In August 2025 they ask their counsel: "Can we use the new Rule 138 and pay the ₹50,000-per-month fee to get an extension?"

The answer is an unqualified no. The application stood abandoned on 2 June 2025 by operation of Section 9(1). No fee, no petition, no Controller discretion can revive it. Lark Engineering's only path is a fresh application — with two painful costs. First, the priority date is lost; the new application takes today's filing date. Second, and worse, Lark Engineerings own pilot deployment — a public use of the invention in the intervening months — may now be citable as prior art against the fresh filing. The Section 31 grace period will not help: a commercial farm pilot is not display at a notified exhibition or a paper before a learned society, and even where Section 31 factually applies, the 2024 Rules require it to be affirmatively claimed on Form 31 with evidence — it is not automatic.

Note also what does not exist here: there is no restoration mechanism for Section 9(1) abandonment, unlike a lapsed patent (which has the Section 60 restoration route on a showing of due care). And Section 21 condonation is irrelevant — that provision, with its Rule 24B/Rule 138 machinery, governs putting an application in order for grant after examination, not the provisional-to-complete conversion.

Item 2: the convention priority window

The twelve-month window under Section 135 for filing a convention application in India, counted from the first application in the convention country, is likewise Act-fixed and mirrors Article 4 of the Paris Convention. Miss it, and the Indian filing cannot claim convention priority; if it is filed anyway claiming a stale priority, that false claim is itself a ground of pre-grant and post-grant opposition under Sections 25(1)(i) and 25(2)(i), and of revocation under Section 64.

Example: Morpho Cards GmbH files in Germany on 10 January 2025 and instructs Indian counsel on 20 January 2026 — ten days late. Rule 138 cannot condone this. Morpho Cards may still file in India without priority, but its own German application, if published in the interim, and any intervening third-party disclosures may stand as prior art. If German Application is published, that usually means the Indian filing is not worth making.

Item 3: the one-year post-grant opposition window

Section 25(2) permits "any person interested" to oppose a granted patent within one year of the publication of grant. That year is written into the Act. The 2024 amendments adjusted the fees and the Opposition Board's internal timelines (Rule 56(4), noted above), but an opponent who wakes up in month thirteen is out of the opposition forum entirely — the remedy shifts to the far heavier machinery of revocation under Section 64 before the High Court, or a counterclaim in infringement proceedings.

Item 4: the eighteen-month restoration outer limit

Where a patent lapses for non-payment of renewal fees, Section 60(1) allows a restoration application within eighteen months from the date the patent ceased to have effect. The Rules govern the procedure inside that window; they cannot stretch the window. A patentee who discovers a lapsed patent in month nineteen — a depressingly common discovery during due diligence for a financing or acquisition — has lost the patent irretrievably.

Item 5 and the messy middle: where the Act/Rules line is blurred

Intellectual honesty requires flagging three timelines where the neat "Act versus Rules" dichotomy gets complicated.

Request for Examination. The number of months (now 31, previously 48) lives in Rule 24B, not the Act — so it is technically Rules-based. But before 2024, Rule 137 expressly excluded RFE delays from condonation, and the Delhi High Court in Carlos Alberto Perez Lafuente v. Union of India (2019) held that the Controller had no authority to extend it — treating it, in effect, as though it were statutory. The 2024 amendment changed this. Rule 138 now permits the purchase of up to six months' extension for the RFE — at ₹50,000 per month for a large entity, ₹10,000 for individuals, startups and small entities. So a missed RFE is no longer a brick wall; it is merely an expensive toll gate. Practitioners who internalised the pre-2024 position should update their advice — and their clients' worst-case memos.

PCT national phase entry (31 months from priority). This deadline flows from the PCT read with Section 138(4) of the Act and Rule 20. The text of Rule 138 is arguably broad enough to cover it — and this has tempted some to argue that a late national phase entry can now be condoned. But the Patent Office's publicly stated position on the 2024 amendments is that it will not condone delay in national phase entry, "unintentional" or otherwise, consistent with India's reservation under PCT Rule 49.6. Treat 31 months as non-extendable in practice, even though the legal foundation is more contested than the Section 9(1)/135/25(2)/60(1) group. No client memo should ever gamble on the contrary.

Section 21 — putting the application in order for grant. The consequence (deemed abandonment for failure to comply with the Act's requirements after examination) sits in Section 21, but the period is expressly delegated to the Rules — and the 2024 amendments give a nine-month effective window for seeking extensions of the FER response through Rule 24B read with Rule 138. So this one is extendable. Do not confuse Section 21 abandonment (curable, at a price) with Section 9(1) abandonment (incurable) merely because both use the word "abandoned."

---

Part III: A Practitioner's Decision Framework

When a client walks in with a missed deadline, the analysis after 2024 runs in three questions.

First, where does the deadline live? If both the period and the consequence are written into the Act — Sections 9(1), 135, 25(2), 60(1) — stop. No fee, no petition, no Controller discretion will fix it. The only levers are a fresh application (for Section 9(1) and Section 135 defaults, accepting the loss of priority and the intervening prior-art exposure), living with opposition or revocation exposure (Section 25(2)), or accepting the loss of the patent (Section 60(1)).

Second, if it lives in the Rules, is it within the Rule 138 window? The request in Form 4 must be made before the expiry of the six-month period following the original deadline. Rule 138 is a lifeline, not a time machine: at month seven, even a Rules-based deadline is beyond rescue.

Third, price the extension against the value of the right. At ₹50,000 per month for a large entity, a six-month RFE extension costs ₹3,00,000 in official fees alone. For a portfolio filing of marginal value, abandonment may be the rational choice; for a crown-jewel application, it is the cheapest insurance the client will ever buy.

Conclusion

The Patent (Amendment) Rules, 2024 represent the most applicant-friendly recalibration of Indian patent procedure in a generation: shorter pendency through the 31-month RFE, lighter compliance through the reformed Form 3 and triennial Form 27, statutory clarity on divisionals, recognition for inventors, discounted renewals — and, above all, a transparent, fee-based safety net under Rule 138 for nearly every procedural stumble.

But the safety net is strung only beneath the Rules. The Act's own deadlines — the twelve months of Section 9(1), the convention year of Section 135, the opposition year of Section 25(2), the restoration limit of Section 60(1) — remain exactly what they were: absolute. The 2024 amendments have made Indian patent practice more forgiving, not forgiving. The competent practitioner's calendar, therefore, now carries two colours of entry: the deadlines you can buy back, and the deadlines that, once gone, are gone forever. Know which is which before you promise a client anything.

---

This article is for general information only and does not constitute legal advice. Specific matters should be assessed on their own facts. The official fee figures mentioned are as prescribed under the Patent (Amendment) Rules, 2024 and should be verified against the current First Schedule before filing.